# Safe Medication Practice NPSA - UK

## **David Cousins**




Patient Safety 2006


# The role of the NPSA

- The NPSA is a special health authority within the National Health Service in the UK with a role to:
- collect and analyse information on patient safety incidents (adverse events) in the NHS
- assimilate other safety related information from within the UK and worldwide
- learn lessons and ensure that they are fed back into practice
- where risks are identified produce solutions to prevent harm, specify national goals, establish mechanisms to track progress

# National Reporting & Learning System (NRLS)





7000 6000 5000 Number of Incidents 4000 3000 2000 1000 0 Jan-05 Feb-05 Apr-05 May-05 Jun-05 Jul-05 Aug-05 Jan-06 Apr-06 May-06 Jun-06 Mar-05 Sep-05 Oct-05 Nov-05 Dec-05 Feb-06 Mar-06




Month

# NRLS Medication Incidents – Reported Degree of Harm






# **NRLS Medication Incidents – Stage**



# **NRLS Medication Incidents – Type %**



# **Patient Safety Feedback**

Building a memory: preventing harm, reducing risks and improving patient safety

The first report of the National Reporting and Learning System and the Patient Safety Observatory

#### July 2005



NHS National Patient Safety Agency

With safety in mind: mental health services and patient safety Patient Safety Observatory Report 2 | July 2006



National Patient Safety Agency

### PATIENT SAFETY ALERT

#### PROBLEM:

Research in UK and elsewhere has identified a risk to patients from errors occurring during intravenous administration of potassium solutions.

Potassium chloride concentrate solution can be fatal if given inappropriately.

#### ACTION FOR NHS BY 31 OCTOBER 2002:

This alert sets out action, including initial action in the following areas:

- Storage and handling of potassium chloride concentrate and other strong potassium solutions
- 2. Preparation of dilute solutions containing potassium
- 3. Prescription of solutions containing potassium
- 4. Checking use of strong potassium solutions in clinical areas

#### For the attention of:

**Chief Executives of NHS Trusts and Primary Care Trusts** 

#### For action by:

Chief Pharmacists and pharmaceutical advisers in NHS Trusts and Primary Care Trusts

#### For information to:

Regional Directors of Health and Social Care Chief Executives of Strategic Health Authorities Directors of Public Health: Regional, StHA, PCT Medical Directors Directors of Nursing Risk Managers Lead Consultants/Clinical Directors – critical care areas Communications Leads Patient Advice and Liaison Service (PALS)



Date: 23 July 2002

## Safer practice notice 12



#### Ensuring safer practice with 30mg doses of diamorphine and morphine

The National Patient Safety Agency (NPSA) has received reports of patient safety incidents involving the administration of 30mg doses of the opiates diamorphine and morphine in primary care locations.

NHS

National Patient Safety Agency

Between January and October 2005, the NPSA received 16 reports that described diamorphine/morphine usage in primary care where 30mg doses were administered to 'opiate nsive' patients (patients who had not previously received lower doses of these opiates) with adverse consequences. A 30mg bolus can be excessive for opiete raive patients and result in overdose, respiratory depression, loss of consciousness or death if support procedures are not implemented.

Some of the incidents reported to the NPSA were the result of staff mistakanly selecting and administering the wrong strength of injection due to similar product names, labaling and packaging. In recent months there have been shortages in the supply of all strengths of diamorphine injections in the NHS and this may have resulted in changes to the medicine products being supplied and used.

This safer practice notice aims to raise awaraness of the risks from inadvartant, use of diamorphine and morphine and makes safer practice recommendations. The risks and recommendations are applicable to all NHS care locations.

#### Action for the NHS

- Undertake risk assessments and ensure safe procedures are in place for labeling, supplying, storing, preparing and administering diamorphine and morphine injections.
- 2 Review therapeutic guidelines for the use of diamorphine and morphine in acute care, including post-administration observation of opiate naive patients.
- 3 Update induction and training for all staff involved in the use of diamorphine and morphine injections to include the risks, safe procedures and therapeutic guidelines.
- 4 Ensure that realowone injection, an antidote to opioid-induced respiratory depression, is available in all clinical locations where diamorphine and morphise injections are not ended as administrand.

## Notice

Immediate action

Action	Z
Update	
Information request	

Ref: NPSA/2006/12

## **Safe Medication Practice Work Streams**

### **Completed/ongoing**

- Potassium Chloride Injection
- Methotrexate tablets
- Labelling and packaging
- Diamorphine/morphine
  Injections

### Current

- Anticoagulants
- Wrong route errors
- - oral liquid medicines
- - epidural medicines
- Injectable medicines

# **More** information

## www.npsa.nhs.uk



A new web portal, trying to provide healthcare professionals with the best available evidence and tools to improve patient safety.